Key Highlights
- David Pyrce, a veteran with over 30 years in the biotech and pharma industry, is appointed as the new CEO of Cognigenics, Inc.
- Cognigenics focuses on RNA-based gene therapies targeting cognitive decline, anxiety, and other neurodegenerative and neuropsychiatric diseases.
- John Mee, former CEO, transitions to Founder and President, continuing his contribution to the company.
- Pyrce brings extensive experience in capital markets, enhancing Cognigenics’ strategic goals in mental health treatments.
- Cognigenics is advancing in preclinical studies and RNA-based therapies for cognitive impairment and Alzheimer’s Disease.
Source: Business Wire
Notable Quotes
- “The potential of RNA-based therapeutics in transforming mental health care and neurodegenerative disorders is immense, and I look forward to contributing to the company’s innovative journey, driving growth, and delivering value to our stakeholders.” – David Pyrce, CEO at Cognigenics, Inc
- “David’s appointment comes at a pivotal time for Cognigenics as we advance in our mission to revolutionize mental health treatments. His deep understanding of the healthcare industry, combined with his extensive experience in capital markets, aligns perfectly with our strategic goals.” – Dr. Dean Radin, Chairman at Cognigenics, Inc
SoH's Take
The appointment of David Pyrce as CEO of Cognigenics, Inc. is a strategic move that combines his extensive background in biotech, pharma, and capital markets with Cognigenics’ innovative approach to RNA-based gene therapies. This alignment promises to bolster the company’s position in the evolving landscape of mental health and neurodegenerative disease treatments. Pyrce’s leadership is anticipated to drive significant growth and innovation, particularly as the company advances in crucial preclinical studies. His appointment signals a positive trajectory for Cognigenics, potentially leading to breakthroughs in the treatment of cognitive impairment, anxiety, and Alzheimer’s Disease. The focus on RNA-based therapies, a rapidly growing field, underscores Cognigenics’ commitment to pioneering non-invasive, targeted treatments that could revolutionize mental health care.
